The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
RBM10 mutation as a potential negative prognostic/predictive biomarker to therapy in non-small-cell lung cancer.
 
Amanda Reyes
No Relationships to Disclose
 
Michelle Afkhami
No Relationships to Disclose
 
Ramya Muddasani
Stock and Other Ownership Interests - Abbvie; Abbvie; Actinium Pharmaceuticals; Actinium Pharmaceuticals (I); Advaxis (I); Agenus; Agenus (I); Aprea Therapeutics; Aprea Therapeutics (I); Athenex (I); AVEO (I); Cellectar; Cellectar (I); crispr therapeutics (I); Curis (I); DelMar Pharmaceuticals; DelMar Pharmaceuticals (I); DelMar Pharmaceuticals (I); Epizyme; Epizyme (I); Forty Seven; Forty Seven (I); Gritstone Bio (I); Heat Biologics (I); Immunomedics; Immunomedics (I); Mereo BioPharma (I); NantHealth (I); NantKwest,; NantKwest, (I); Novavax (I); Onconova Therapeutics; Onconova Therapeutics (I); Pfizer (I); Portola Pharmaceuticals (I); Vaxart
 
Xiaochen Li
No Relationships to Disclose
 
Erminia Massarelli
Honoraria - AstraZeneca; Physicans' Education Resource
Consulting or Advisory Role - Abbvie; Bristol Myers Squibb Foundation; Daiichi-Sankyo; Fusion Pharmaceuticals; Gilead Sciences; Iovance Biotherapeutics; Janssen Scientific Affairs; Mirati Therapeutics; Sanofi
Travel, Accommodations, Expenses - Physicans' Education Resource
 
Ravi Salgia
No Relationships to Disclose